Acquisitions in Alzheimer’s drug development have soared, with deal value jumping from $2 billion in 2022 to nearly $18 ...

Japanese drugmaker Shionogi (TYO: 4507) has filed a supplemental application in Japan to broaden the use of its oral ...

Chinese biopharma Hutchmed today announced that the New Drug Application (NDA) for the combination of Orpathys (savolitinib) ...

US pharma major AbbVie is to buy Capstan Therapeutics, a San Diego-based biotech advancing in vivo engineering of cells ...

US mRNA specialist Moderna today announced positive results from a Phase III efficacy study (P304) evaluating the relative ...

US biotech major Amgen today announced the Phase III FORTITUDE-101 clinical trial evaluating first-line bemarituzumab plus ...

The nontuberculous mycobacteria (NTM) market across the seven major markets (7MM: the USA, France, Germany, Italy, Span, the UK and Japan) is forecast to grow at a compound annual growth rate (CAGR) ...

US biopharma Alto Neuroscience, a firm focused on the development of novel precision medicines for neuropsychiatric disorders ...

US biotech major Amgen, a late comer to the growing obesity treatment space, released new data showing that its MariTide ...

Swedish Orphan Biovitrum, the Nordic biotech also known as Sobi, on Friday announced that the US Food and Drug Administration ...

US biotech Arbutus Biopharma (Nasdaq: ABUS) has reacquired the rights to its lead hepatitis B candidate, imdusiran (AB-729), ...

Belgian pharma UCB today announced that the Phase III study investigating the safety and efficacy of adjunctive fenfluramine ...